Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. - Wikidata - wikimedia - TriplyDB

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

http://www.wikidata.org/entity/Q33804713

about

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Metabolic consequences of oncogenic IDH mutations Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres Isocitrate dehydrogenase mutations in gliomas Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.Glioma Subclassifications and Their Clinical Significance.Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Targeting Metabolism for Cancer Therapy.Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Adapting the drivers to the road: a new strategy for cancer evolution?Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.Biological Role and Therapeutic Potential of IDH Mutations in Cancer.The p53 Pathway in Glioblastoma IDH1 is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment

P2860

Q28066926-06D76195-6D33-42FF-A2D3-964CC7BD3010 Q28082949-C11D84A5-E735-4FA7-A0E1-67E48533AA0B Q30943327-A7462AAD-C936-4821-8B16-CB0D95771838 Q35543657-996409A8-F7FE-4889-80E0-D67B6066B032 Q36288179-141634E5-F44C-440A-A599-67807127E2DE Q36367409-855DBDDE-4E5F-49BD-A0B6-822EDA44021E Q36385589-1C23204F-746D-49A2-B616-10B243D0EDC0 Q36457608-E8E0856A-7E95-4590-B231-80E974A897A1 Q36955557-FF227D1E-711D-452F-93E0-462B5FBDA4B2 Q37230411-17D4F1D1-9EC2-4F0A-9C2C-4B79C282A29A Q38382618-8194A65D-615D-4DBA-B14B-773C0D50A41C Q38400073-C3EA6BCD-BD6B-4AD9-9CD3-A698DED45E70 Q38480437-93BDA62E-E0B9-43E5-9536-A147202B6727 Q38747746-78C1178A-C32C-4E65-A4A1-640598B4BCB2 Q38849515-9BBD1584-FAEA-46F9-9B4A-95CD4F9F5E2E Q38873014-D4032D44-F2A6-419C-810F-84DCFDF4540D Q39167472-1EBC58A1-9D1A-43CD-9E29-CADB8F131508 Q39417407-5AE6AB23-C977-44C3-91DB-ADDFE1FB34A5 Q40879813-7442533F-AC2A-43FA-A9B5-E4E212CD724F Q41138932-5F39F457-83DF-4A23-9D0D-6B9620AE20F8 Q42511174-2631419A-95AA-4C1B-8BB4-4E3442A6A8B1 Q46232869-214BCFEB-B606-4CFE-8414-44A8556362D8 Q47153393-66B56890-7E5F-4C48-959F-5D13A9E081AB Q47646742-513CBE0A-C5E6-445D-8825-6FBE99A68EC1 Q47912632-AA4E463B-8489-4AFA-B6B6-740609E3D2D3 Q48292830-B18C9DED-B79A-4034-ABA5-84668D1882FA Q52099170-DF50E09E-BA6E-46DC-BA3E-364E362C291B Q55456962-53BEBD7A-CD44-4550-8E20-0EC047507D2D Q57162865-6C149AFF-CF83-4E35-A0AA-E9155F33FE66 Q58738690-3563ABD0-B044-45D2-90CA-C9C77D493968

P2860

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

http://www.wikidata.org/entity/Q33804713

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@ast

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@en

type

label

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@ast

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@en

prefLabel

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@ast

Targetable signaling pathway m ...... enotype in IDH-mutant gliomas.

@en

P1433

Q33804713-074D4012-1E50-48FA-B2E3-EB96742EB0CE

P1476

Q33804713-B81D1F09-6C61-487A-8C14-40DF7628F9CB

P2093

Q33804713-3F4629B5-0AFC-4FA2-926D-063A6B04A1A6

Q33804713-518AD899-A35E-410A-B448-C301CFA4974D

Q33804713-54EE2B53-CD16-4F01-B393-16C1D4BFA0C9

Q33804713-65627E6B-0F5E-4107-B906-011D82C35E42

Q33804713-786518EC-83CC-41BF-A6F1-B572011839F6

Q33804713-7ED0C00E-8B2C-4B07-85CF-FBBC52CE97C3

Q33804713-7F8E94C2-DEBA-45D3-BEEC-738AF93F9E0A

Q33804713-8422C012-7432-4887-8001-B028A759F555

Q33804713-A24C5CBA-52CB-4DFC-82D2-B23BD4FC5C52

Q33804713-A4CB17FF-307A-4057-88B2-C9A688DDC527

P2860

Q33804713-00856098-3ADA-4580-A77B-7B532A4BD395

Q33804713-01EE12E3-513E-4428-89C1-A4AA65883F44

Q33804713-09DAADDB-BD96-4306-877F-C5BAB3BD8346

Q33804713-0A71485C-26B2-46DF-9464-3F9F34F4F332

Q33804713-0BD9E636-45E4-455F-BB3C-99B84E3426FD

Q33804713-16776C4D-11B5-4C81-83F5-47EA5958831B

Q33804713-1F78E765-C1AD-4F44-A0EE-64EA12E00A28

Q33804713-204D23AC-1212-4E72-BD1C-DF481A45FEAF

Q33804713-2E159BA0-9A10-40FE-B464-E0F05EF122E3

Q33804713-3C917AEC-01E2-4FFC-985A-C87B9CC785CF

P304

Q33804713-8ABCFDA2-CE45-4A40-AA93-2D89C1919038

P31

Q33804713-9321DEBA-570E-40DE-89D0-CF7EE26E4D5C

P356

Q33804713-3E05E729-8536-46FB-8EF1-97B78558FFB9

P407

Q33804713-D5447080-E57A-420F-93D4-D45E8A8EEF7F

P433

Q33804713-E5A4328A-C424-4D45-A4B6-FEB670C65308

P478

Q33804713-206BF135-D708-468F-A932-6DBA9908AAF9

P50

Q33804713-21CFD29F-6B55-4827-9A05-ADF3D4CE6FFA

Q33804713-6B288971-F4FC-4F39-9322-974006CF39D4

Q33804713-7EF4BF88-F603-4D1E-8DE5-2423C397B0AE

P577

Q33804713-7A56D4EE-FF3B-4910-A8DA-3C245814DC54

P5875

Q33804713-60973475-E820-4350-8243-D4F138488109

P698

Q33804713-C4282610-35CA-42DD-8712-C724853ACBE6

P932

Q33804713-B9588304-38F3-46FB-B3F6-BF43F9FD8AF9

P356

1078-0432.CCR-13-3052

P1433

Clinical Cancer Research

P1476

Targetable signaling pathway m ...... henotype in IDH-mutant gliomas

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Andrew S Chi

http://www.w3.org/2001/XMLSchema#string

Darrell R Borger

http://www.w3.org/2001/XMLSchema#string

Dora Dias-Santagata

http://www.w3.org/2001/XMLSchema#string

Franziska Loebel

http://www.w3.org/2001/XMLSchema#string

Hiroaki Wakimoto

http://www.w3.org/2001/XMLSchema#string

James C Kim

http://www.w3.org/2001/XMLSchema#string

Juxiang Chen

http://www.w3.org/2001/XMLSchema#string

Kensuke Tateishi

http://www.w3.org/2001/XMLSchema#string

Leif W Ellisen

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

P304

2898-2909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-3052

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Daniel P Cahill

Sarah-maria Fendt

P577

2014-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261516400

http://www.w3.org/2001/XMLSchema#string

P698

24714777

http://www.w3.org/2001/XMLSchema#string

P932

4070445

http://www.w3.org/2001/XMLSchema#string